Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paxalisib - Kazia Therapeutics

Drug Profile

Paxalisib - Kazia Therapeutics

Alternative Names: G-02441729; GDC-0084; RG 7666; SIM-0395

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Alliance for Clinical Trials in Oncology; Dana-Farber Cancer Institute; Genentech; Global Coalition for Adaptive Research; Huntsman Cancer Institute; John Hopkins University; Kazia Therapeutics; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); St. Jude Childrens Research Hospital; University of California; Weill Cornell Medical College
  • Class Amines; Antineoplastics; Morpholines; Oxazines; Purines; Pyrimidines; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rhabdoid tumour; Diffuse intrinsic pontine glioma; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Glioblastoma
  • Phase II Brain metastases; Glioma; Lymphoma
  • Phase I Diffuse intrinsic pontine glioma; Meningeal carcinomatosis
  • Preclinical Malignant melanoma; Rhabdoid tumour

Most Recent Events

  • 21 Mar 2024 Paxalisib licensed to SoVarGen Worldwide excluding China, Hong Kong, Macau, Taiwan
  • 21 Mar 2024 Kazia Therapeutics in collaboration with SoVarGen plans a phase II trial for Partial epilepsies and Tuberous sclerosis in the latter half of 2024
  • 13 Mar 2024 Pacific Pediatric Neuro-Oncology Consortium plans a clincal trial for Rhabdoid tumour (atypical teratoid) (Combination therapy, Second-line therapy or greater)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top